Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review

Vaccine ◽  
2009 ◽  
Vol 27 (52) ◽  
pp. 7242-7243 ◽  
Author(s):  
Maarten J. Postma ◽  
Robin de Vries ◽  
John Roord
PLoS ONE ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. e0177342 ◽  
Author(s):  
Jung Yeon Heo ◽  
Yu Bin Seo ◽  
Won Suk Choi ◽  
Jacob Lee ◽  
Ji Yun Noh ◽  
...  

2015 ◽  
Vol 112 (5) ◽  
pp. E472-E477 ◽  
Author(s):  
Maria A. Riolo ◽  
Pejman Rohani

Pertussis has reemerged as a major public health concern in many countries where it was once considered well controlled. Although the mechanisms responsible for continued pertussis circulation and resurgence remain elusive and contentious, many countries have nevertheless recommended booster vaccinations, the timing and number of which vary widely. Here, using a stochastic, age-stratified transmission model, we searched for cost-effective booster vaccination strategies using a genetic algorithm. We did so assuming four hypothesized mechanisms underpinning contemporary pertussis epidemiology: (I) insufficient coverage, (II) frequent primary vaccine failure, (III) waning of vaccine-derived protection, and (IV) vaccine “leakiness.” For scenarios I–IV, successful booster strategies were identified and varied considerably by mechanism. Especially notable is the inability of booster schedules to alleviate resurgence when vaccines are leaky. Critically, our findings argue that the ultimate effectiveness of vaccine booster schedules will likely depend on correctly pinpointing the causes of resurgence, with misdiagnosis of the problem epidemiologically ineffective and economically costly.


Vaccine ◽  
2022 ◽  
Author(s):  
Motoko Tanaka ◽  
Reiko Okubo ◽  
Shu-Ling Hoshi ◽  
Nobuyuki Ishikawa ◽  
Masahide Kondo

2015 ◽  
Vol 46 (5) ◽  
pp. 1407-1416 ◽  
Author(s):  
Marie-Josée J. Mangen ◽  
Mark H. Rozenbaum ◽  
Susanne M. Huijts ◽  
Cornelis H. van Werkhoven ◽  
Douwe F. Postma ◽  
...  

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65–74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750–17 100). Vaccination of high-risk individuals aged 65–74 years was cost-saving and extension to medium-risk individuals aged 65–74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.


BMC Medicine ◽  
2018 ◽  
Vol 16 (1) ◽  
Author(s):  
P. Bruijning-Verhagen ◽  
J. A. P. van Dongen ◽  
J. D. M. Verberk ◽  
R. Pijnacker ◽  
R. D. van Gaalen ◽  
...  

2013 ◽  
Vol 29 (3) ◽  
pp. 315-322 ◽  
Author(s):  
Ruth Wong ◽  
Suzy Paisley ◽  
Christopher Carroll

Objectives: No guidelines exist in the approach that Evidence Review Groups (ERGs) should take to appraise search methodologies in the manufacturer's submission (MS) in Single Technology Appraisals (STA). As a result, ERGs are left to appraise searches using their own approach. This study investigates the limitations of manufacturers' search methodologies as critiqued by ERGs in published STA reports and to provide a recommended checklist.Methods: Limitations from search critiques in 83 ERG reports published in the NIHR Web site between 2006 and May 2011 were extracted. The limitations were grouped into themes. Comparisons were made between limitations reported in the clinical effectiveness versus cost-effectiveness searches.Results: Twelve themes were identified, six relating to the search strategy, source, limits, filters, translation, reporting, and missing studies. The search strategy theme contained the most limitations. Missing studies were frequently found by the ERG group in the clinical effectiveness searches. The omission of searches by manufacturers for unpublished and ongoing trials was frequently reported by the ERG. By contrast, failure of the manufacturer to report strategies was the most common limitation in the cost-effectiveness searches. Themes with the most frequent limitations in both types of searches are search strategy, reporting and source.Conclusions: It is recommended that a checklist that has reporting, source and search strategy elements be used in the appraisal of manufacturer's searches during the STA process.


2016 ◽  
Vol 23 (6) ◽  
pp. 800-806 ◽  
Author(s):  
Lonzozou Kpanake ◽  
Sadji Gbandey ◽  
Paul Clay Sorum ◽  
Etienne Mullet

In anticipation of a future HIV vaccine, we mapped the different personal positions regarding HIV vaccination of people in Togo. In early 2014, 363 adults indicated their willingness to receive a future HIV vaccine under different conditions varying as a function of five factors: perceived susceptibility to HIV, vaccine effectiveness, perceived severity of AIDS, vaccine cost, and family’s influence. We found five qualitatively different positions: unconditional acceptance (49%), depends on cost/effectiveness ratio (20%), depends on cost (18%), total indecision (10%), and complete reluctance (3%). Accordingly, HIV vaccination strategies in Togo and elsewhere in Africa need to be multifaceted and tailored.


2011 ◽  
Vol 14 (7) ◽  
pp. A447
Author(s):  
L. García-Jurado ◽  
R. Morano ◽  
A. Torné ◽  
A. Malvar ◽  
J.M. Bayas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document